Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134706 · ClinicalTrials.gov registry record · Phase 2
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00134706 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT00134706, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the effects (good and bad) of the combination of docetaxel and carboplatin for patients who have progressive prostate cancer after chemotherapy with drugs such as docetaxel. The investigators are also studying whether the measurement of two proteins in the blood may predict who will respond to the combination of docetaxel and carboplatin.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-01 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134706
The ClinicalTrials.gov registry entry for NCT00134706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT00134706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00134706 about?
NCT00134706 is a clinical study titled "A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer". The purpose of this study is to look at the effects (good and bad) of the combination of docetaxel and carboplatin for patients who have progressive prostate cancer after chemotherapy with drugs such as docetaxel. The investigators are also studying whether the measurement of two proteins in the blo...
What is the current status of trial NCT00134706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-01. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00134706?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG).
Who is sponsoring clinical trial NCT00134706?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.